Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find out if Revlimid can help to control the
disease in patients with relapsed/refractory acute myelogenous leukemia (AML) or high-risk
myelodysplastic syndrome (MDS) with abnormalities in chromosome number 5. The safety of this
treatment will also be studied.